As of Friday close, TransMedics Group Inc.’s (NASDAQ:TMDX) stock was down -$7.27, moving down -8.31 percent to $80.26. The average number of shares traded per day over the past five days has been 1,002,600 shares. 2 times new highs have been achieved over the past 5 days, with a -$11.04 fall in that time frame. In the last twenty days, the average volume was 563,305, while in the previous 50 days, it was 529,980.
Since last month, TMDX stock retreated -1.73%. Shares of the company fell to $75.00 on 08/04/23, the lowest level in the past month. A 52-week high of $99.63 was reached on 07/19/23 after having rallying from a 52-week low of $35.56. Since the beginning of this year, TMDX’s stock price has risen by 30.04% or $18.54, and marked a new high 25 times. However, the stock has declined by -19.44% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TMDX stock investors should be aware that TransMedics Group Inc. (TMDX) stock had its last reported insider trading activity 4 days ago on Aug 01. Hassanein Waleed H, the President & CEO of the company, disposed of 7,500 shares for $93.06 on Aug 01. It resulted in a $697,929 divestment by the insider. Khayal Tamer I sold 5,000 shares at an average price of $95.37 on Jul 18. The insider now owns 14,375 shares following the transaction. On Jul 13, Chief Commercial Officer Khayal Tamer I sold 2,974 shares at $90.05 apiece. The transaction was valued at $267,809.
Valuation Metrics
The stock’s beta is 1.47. Besides these, the trailing price-to-sales (P/S) ratio of 21.51, the price-to-book (PB) ratio of 13.44.
Financial Health
In the three months ended June 29, TransMedics Group Inc.’s quick ratio stood at 8.30, while its current ratio was 9.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.31, and the total debt-to-equity ratio was 0.31. On the profitability front, the trailing twelve-month gross margin is 68.80% percent. In the year ended June 29, EBITDA margin amounted to -29.15%, whereas operating margins totaled -19.70%. Based on annual data, TMDX earned $65.27 million in gross profit and brought in $93.46 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -12.60%. Return on equity (ROE) for the past 12 months was -18.30%.
In TransMedics Group Inc.’s quarter-end financial report for June 29, it reported total debt of $58.8 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TMDX’s revenue rose 61.78% to $31.38 million during the quarter, while net income inched up to $41.55 million. While analysts expected TransMedics Group Inc. to report -$0.13 quarterly earnings, the actual figure was -$0.03 per share, beating the consensus estimate by 76.90%. During the quarter, the company generated -$0.8 million in EBITDA. The liabilities of TransMedics Group Inc. were 94.46 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $32.55 million.
Technical Picture
This quick technical analysis looks at TransMedics Group Inc.’s (TMDX) price momentum. With a historical volatility rate of 54.39%, the RSI 9-day stood at 27.99% on 04 August.
With respect to its five-day moving average, the current TransMedics Group Inc. price is down by -12.09% percent or -$11.04. At present, TMDX shares trade -1.57% below its 20-day simple moving average and +9.93% percent above its 100-day simple moving average. However, the stock is currently trading approximately +12.42% above its SMA50 and +97.39% above its SMA200.
Stochastic coefficient K was 11.21% and Stochastic coefficient D was 21.96%, while ATR was 4.53. Given the Stochastic reading of 21.36% for the 14-day period, the RSI (14) reading has been calculated as 36.45%. As of today, the MACD Oscillator reading stands at -4.28, while the 14-day reading stands at -5.21.
Analyst Ratings
Robert W. Baird launched its rating on TransMedics Group Inc. (NASDAQ: TMDX) to an Outperform in a note to investors on July 19, 2023. TransMedics Group Inc. (TMDX) has been rated Buy by analysts. According to 0 brokerage firms, TMDX is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate TransMedics Group Inc. stock as buy, with 5 recommending it as overweight.
